Are you at risk?
PHARMAC-funded direct acting antivirals drugs and their treatment numbers since 2019 as follows:
Since February 2019, around 5,000 New Zealanders with hepatitis C have been treated with Maviret, a new direct-acting antiviral treatment funded by PHARMAC.
Maviret is simple to administer, has fewer side effects than previous treatments, and can potentially cure 98 percent of people with chronic hepatitis C.
Refer to the PHARMAC website for further details about the funded treatment options and for information for people with hepatitis C, for prescribers and for pharmacists: